Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07000513

HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria

Long-acting injectable antiretroviral therapy (LAI ART) and Pre-Exposure Prophylaxis (LAI PrEP) have the potential to transform HIV treatment and prevention, especially in reaching individuals such as commercial minibus drivers who have minimal or no contact with traditional health facilities. The project proposes to use a culturally appropriate and community-engaged approach to promote the uptake of HIV self-testing, LAI-ART, and LAI-PrEP among commercial minibus drivers in Nigeria by engaging commercial minibus drivers as peer educators/research facilitators.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

HIV

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

About this study

Commercial minibus drivers constitute a large social network of highly mobile men who work long and demanding hours, are at increased risk for HIV, and have limited time to seek health services for HIV. In our preliminary work, our team found a high HIV seropositivity rate of 12.5% among 407 commercial minibus drivers in Nigeria, a prevalence that is nine times higher than the national HIV average. Despite the high willingness to test for HIV among the drivers, the mobile nature of their work poses substantial barriers for those living with HIV to initiate and adhere to antiretroviral therapy (ART) and for those who are HIV-negative and are at risk for HIV to obtain pre-exposure prophylaxis (PrEP). Therefore, innovative strategies such as HIV self-testing (HIVST), which allows individuals to test at home or in private, and long-actinginjectable ART (LAI ART) or LAI PrEP may work better to address the barriers that impede commercial drivers from accessing HIV testing, prevention, and treatment services. The investigators have recently evaluated a youth-friendly HIVST intervention combined with linkage to PrEP in Nigeria as part of an NIH-funded project called ITEST: Innovative Tools to Expand Youthfriendly HIV Self-Testing (UH3HD096929). The investigators propose to leverage our established research program in Nigeria in collaboration with the National Institute of Medical Research to implement a tailored ITEST intervention for commercial minibus drivers (ITEST LAIs), which will include male peer-led distribution of HIV self-testing kits combined with demand creation for both oral and LAI modalities of ART and PrEP. The multi-disciplinary research team proposes a hybrid type I effectiveness-implementation study to assess clinical and implementation determinants outcomes simultaneously.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male commercial minibus drivers who have worked as a driver for at least 6 months
  • 18 years old or older
  • Currently and planning on residing in one of the LGAs during the next 12 months
  • Owning a mobile phone

Exclusion criteria

  • Known HIV positivity
  • Not ability to provide informed consent3
  • No access to a cell phone

Treatment and study plan

ITEST-LAI

Behavioral

The ITEST-LAI intervention includes male peer-led HIVST distribution and promotion, linkage to male-friendly clinics for confirmatory testing and follow-up care, peer support and technical assistance to address implementation challenges, and continuous monitoring and feedback for male peer educators and research facilitators (MPERFs).

Primary outcomes

  1. ART or PrEP Initiation

    Time frame: Baseline and follow-up surveys at 6-,12-, 18-, and 24 months

    Use of patient records and self-report to determine initiation of HIV treatment or preventive medications.

Secondary outcomes

  1. HIV Testing

    Time frame: Baseline and follow-up surveys at 6-,12-, 18-, and 24-months

    Use of patient records and self-report to determine HIV testing behavior (including use of HIVST and confirmatory testing in clinics).

  2. ART Adherence

    Time frame: Baseline and follow-up surveys at 6-,12-, 18-, and 24-months

    Use of self-report and hair sample to measure medication adherence.

  3. PrEP Adherence

    Time frame: Baseline and follow-up surveys at 6-,12-, 18-, and 24-months

    Use of hair samples and self-report to measure medication adherence.

  4. Viral Load Supression

    Time frame: Baseline and follow-up surveys at 6-,12-, 18-, and 24-months

    Use of blood samples to measure viral load suppression among those who received an HIV diagnosis.

  5. HIV Acquisition

    Time frame: Baseline and follow-up surveys at 6-,12-, 18-, and 24-months

    Use of blood samples, self-report, and patient records to measure seroconversion among study participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Donaldson F Conserve, PhD

CONTACT

[email protected]

917-443-6124

Ucheoma Nwaozuru, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

George Washington University

Other

Collaborators

  • The George Washington University Milken Institute School of Public Health (GWU)

Registry information

Official study title

Innovative Tools to Expand HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs)

Acronym: ITEST-LAI

Important dates

Study start
2027
Primary completion
2029
Study completion
2029
First posted
Jun 3, 2025
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.